Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial.

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Radiology, Nuclear Medicine And Imaging

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.103